These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1832996)

  • 1. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease.
    McCarthy PL; Abhyankar S; Neben S; Newman G; Sieff C; Thompson RC; Burakoff SJ; Ferrara JL
    Blood; 1991 Oct; 78(8):1915-8. PubMed ID: 1832996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.
    Antin JH; Weisdorf D; Neuberg D; Nicklow R; Clouthier S; Lee SJ; Alyea E; McGarigle C; Blazar BR; Sonis S; Soiffer RJ; Ferrara JL
    Blood; 2002 Nov; 100(10):3479-82. PubMed ID: 12393661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
    Antin JH; Weinstein HJ; Guinan EC; McCarthy P; Bierer BE; Gilliland DG; Parsons SK; Ballen KK; Rimm IJ; Falzarano G
    Blood; 1994 Aug; 84(4):1342-8. PubMed ID: 8049450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro.
    Emmanouilides CE; Luo J; Baldwin G; Buckley D; Lau P; Lopez E; Tabibzadeh S; Yu J; Wolin M; Rigor R; Territo M; Black AC
    Bone Marrow Transplant; 1996 Aug; 18(2):369-75. PubMed ID: 8864448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model.
    Yang YG; Dey B; Sergio JJ; Sykes M
    Transplantation; 1997 Nov; 64(9):1343-52. PubMed ID: 9371678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
    Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
    Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
    McIntyre KW; Stepan GJ; Kolinsky KD; Benjamin WR; Plocinski JM; Kaffka KL; Campen CA; Chizzonite RA; Kilian PL
    J Exp Med; 1991 Apr; 173(4):931-9. PubMed ID: 1826128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice.
    Vallera DA; Taylor PA; Vannice JL; Panoskaltsis-Mortari A; Blazar BR
    Transplantation; 1995 Dec; 60(11):1371-4. PubMed ID: 8525541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens.
    Abhyankar S; Gilliland DG; Ferrara JL
    Transplantation; 1993 Dec; 56(6):1518-23. PubMed ID: 8279027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
    J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.
    Krijanovski OI; Hill GR; Cooke KR; Teshima T; Crawford JM; Brinson YS; Ferrara JL
    Blood; 1999 Jul; 94(2):825-31. PubMed ID: 10397751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation.
    Xun CQ; Tsuchida M; Thompson JS
    Transplantation; 1997 Jul; 64(2):297-302. PubMed ID: 9256191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease by anti IL-7Ralpha antibody.
    Chung B; Dudl EP; Min D; Barsky L; Smiley N; Weinberg KI
    Blood; 2007 Oct; 110(8):2803-10. PubMed ID: 17595335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.